SCHEMBL25015185

SCHEMBL25015185

C=CC(=O)OCCSc1ccc(C#Cc2ccc(CSc3ccc(C#Cc4ccc(CCOC(=O)C=C)cc4)cc3)cc2C)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 11/20 0.40
CHRM2 P08172 1/20 0.36
S1PR1 P21453 1/20 0.36
FPR1 P21462 1/20 0.36
FPR3 P25089 1/20 0.36
GPR183 P32249 1/20 0.36
APLNR P35414 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
GPR65 Q8IYL9 1/20 0.36
ACACB O00763 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
RECQL P46063 1/20 0.33
THRB P10828 2/20 0.33
PPARA Q07869 3/20 0.32
PPARD Q03181 2/20 0.32
PPARG P37231 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25015298 0.87 FFAR1 (0.43) FFAR1CHRM2S1PR1FPR1FPR3
SCHEMBL25015617 0.81 ACACB (0.36) FFAR1CHRM2S1PR1FPR1FPR3
SCHEMBL25015189 0.79 ACACB (0.37) FFAR1ACACBPPARAPPARD
SCHEMBL25015136 0.77 ACACB (0.43) FFAR1CHRM2S1PR1FPR1FPR3
SCHEMBL25015302 0.77 PPARD (0.42) FFAR1FFAR4ACACBTHRBPPARA
SCHEMBL24806608 0.76 THRB (0.37) FFAR1ACACBCYP1A2CYP3A4CYP2C19
SCHEMBL24806601 0.75 FFAR1 (0.43) FFAR1CHRM2S1PR1FPR1FPR3
SCHEMBL25015300 0.75 MAOA (0.36) FFAR1ACACBTHRBPPARAPPARD
SCHEMBL19773519 0.75 THRB (0.45) FFAR1CHRM2S1PR1FPR1FPR3
SCHEMBL22862352 0.74 THRB (0.51) FFAR1FFAR4ACACBCYP3A4THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230042009-A1 COMPOUND, COMPOSITION, CURED SUBSTANCE, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT FUJIFILM CORPORATION (JP) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230042009-A1 COMPOUND, COMPOSITION, CURED SUBSTANCE, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT SP1, C5, ZYX FFAR1 2652/4885CHRM2 618/4885S1PR1 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.